Discover sources of inflammatory disease progression that translate to therapeutic insights
IsoPlexis detects the small groups of highly dysfunctional immune cells that drive progression across inflammatory diseases, translating this information to therapeutic insights to help you advance your discovery & development programs.
“Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI … can we start to differentiate products.”
Detect the small potent cell subsets that make the difference
Discover differences in T cell subtypes that correlate with SLE (systemic lupus) progression.
Optimize targeting in Inflammatory & Autoimmune Disease
Reveal optimal targets by uncovering the innate cell mechanism driving disease progression.
Correlate data with response to predict clinical outcome
Stratify patients by CRS (cytokine release syndrome) in cell therapy, pre-infusion.